EurekaMag
+ Translate
+ Most Popular
The pigeon tick (Argas reflexus): its biology, ecology, and epidemiological aspects
Prevalence of hemoglobin abnormalities in Kebili (Tunisian South)
Lipogranuloma: a preventable complication of dacryocystorhinostomy
Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency
Bees from the Belgian Congo. The acraensis group of Anthophora
Placing gingival retraction cord
Total serum IgE, allergy skin testing, and the radioallergosorbent test for the diagnosis of allergy in asthmatic children
Acariens plumicoles Analgesoidea parasites des oiseaux du Maroc
Injuries of terminal phalanges of the fingers in children
Biology of flowering and nectar production in pear (Pyrus communis)
Das Reliktvorkommen der Aspisviper (Vipera aspis L.) im Schwarzwald
Hydrological modelling of drained blanket peatland
Pathologic morphology and clinical significance of the anomalous origin of the left circumflex coronary artery from the right coronary artery. General review and autopsy analysis of 30 cases
Cyto genetic analyses of lymphocyte cultures after exposure to calcium cyclamate
Axelrodia riesei, a new characoid fish from Upper Rio Meta in Colombia With remarks concerning the genus Axelrodia and description of a similar, sympatric, Hyphessobrycon-species
Favorable evolution of a case of tuberculosis of pancreas under antibiotic action
RIFM fragrance ingredient safety assessment, Valencene, CAS Registry Number 4630-07-3
Parenteral microemulsions: an overview
Temperate pasture: management for grazing and conservation
Evaluation of a new coprocessed compound based on lactose and maize starch for tablet formulation
Thermal expansion and cracking of three confined water-saturated igneous rocks to 800C
Revision of the genera of the tribe Stigmoderini (Coleoptera: Buprestidae) a discussion of phylogenetic relationships
Anal tuberculosis. Report of a case
Gastric tuberculosis in the past and present
Adaptive responses of the cardiovascular system to prolonged spaceflight conditions: assessment with Holter monitoring

Neuroprotection for preterm infants with antenatal magnesium sulphate


Neuroprotection for preterm infants with antenatal magnesium sulphate



Journal de Gynecologie Obstetrique et Biologie de la Reproduction 45(10): 1418-1433



ISSN/ISBN: 0368-2315

PMID: 28166926

DOI: 10.1016/j.jgyn.2016.09.028

To evaluate in preterm born children the neuroprotective benefits and the risks, at short- and long-term outcome, of the antenatal administration of magnesium sulphate (MgSO4) in women at imminent risk of preterm delivery. Computer databases Medline, the Cochrane Library and the recommendations of various international scientific societies. Given the demonstrated benefit of antenatal MgSO4 intravenous administration on the reduction of cerebral palsy rates and the improvement of motor development in children born preterm, it is recommended for all women whose imminent delivery is expected or programmed before 32 weeks of gestation (WG) (grade A). The analysis of the literature finds no argument for greater benefit of antenatal MgSO4 administration in sub-groups of gestational age, or depending on the type of pregnancy (single or multiple pregnancy) or with the cause of preterm birth (NP2). Its administration is recommended before 32 WG, if single or multiple pregnancy, whatever the cause of prematurity (grade B). It is recommended 4g loading dose (professional consensus). With a loading dose of 4g intravenous (IV) in 20min, the serum magnesium is lower than with intramuscular suggesting a preference for the IV route (professional consensus). It is proposed to use a maintenance dose of 1g/h until delivery with a maximum recommended duration of 12hours without exceeding a cumulative dose of 50g (professional consensus). These doses are without severe adverse maternal side effects or adverse effects in newborns at short- and medium-term outcome (NP1). It is recommended to administer magnesium sulfate to the women at high risk of imminent preterm birth before 32 WG, whether expected or planned (grade A), with a 4g IV loading dose followed by a maintenance dose of 1g/h for 12hours (professional consensus), the pregnancy is single or multiple, whatever the cause of prematurity (professional consensus).

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 060012584

Download citation: RISBibTeXText

Related references

Antenatal magnesium sulphate neuroprotection in the preterm infant. Seminars in Fetal and Neonatal Medicine 12(4): 311-317, 2007

Need for resuscitation in preterm neonates less than 32 weeks treated with antenatal magnesium sulphate for neuroprotection. Revista Chilena de Pediatria 87(4): 261-267, 2016

Antenatal exposure to magnesium sulfate and neuroprotection in preterm infants. Obstetrics and Gynecology Clinics of North America 38(2): 351-66 Xi, 2011

Survey on use of antenatal magnesium sulphate for fetal neuroprotection prior to preterm birth in Australia and New Zealand - Ongoing barriers and enablers. Australian and New Zealand Journal of Obstetrics and Gynaecology 60(1): 44-48, 2020

Implementation of an antenatal magnesium sulfate protocol for fetal neuroprotection in preterm infants. Scientific Reports 5: 14732, 2015

Maternal adverse effects with different loading infusion rates of antenatal magnesium sulphate for preterm fetal neuroprotection: the IRIS randomised trial. Bjog: An International Journal of Obstetrics and Gynaecology 121(5): 595-603, 2014

Antenatal magnesium sulphate to prevent cerebral palsy in very preterm infants. Bjog: An International Journal of Obstetrics and Gynaecology 118(7): 891, 2011

Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis. Obstetrics and Gynecology 114(2 Pt 1): 354-364, 2009

Effects of Antenatal Exposure to Magnesium Sulfate on Neuroprotection and Mortality in Preterm Infants: A Meta-analysis. Obstetrics and Gynecology (New York 1953) 114(2): 354-364, 2009

Protection of brain development by antenatal magnesium sulphate for infants born preterm. Developmental Medicine and Child Neurology 61(1): 25-30, 2019

Does antenatal magnesium sulphate prevent cerebral palsy in preterm infants? The final trial?. 2012

A report from #BlueJC: are we convinced antenatal magnesium sulphate can prevent cerebral palsy in preterm infants?. BJOG: an international journal of obstetrics and gynaecology 121(5): 647, 2014

Comparison of the effects of antenatal magnesium sulphate and ritodrine exposure on circulatory adaptation in preterm infants. Clinical Physiology and Functional Imaging 22(1): 13-17, 2002

Does Antenatal Administration of Magnesium Sulphate Prevent Cerebral Palsy and Mortality in Preterm Infants? A Study Protocol. Aims Public Health 2(4): 727-729, 2015

Antenatal magnesium sulphate for the prevention of cerebral palsy in infants born preterm: a double-blind, randomised, placebo-controlled, multi-centre trial. BJOG: An International Journal of Obstetrics and Gynaecology 127(10): 1217-1225, 2020